Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224766 | 0.81 | PDE4B (0.63) | PDE4BKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3222508 | 0.80 | PDE4B (0.45) | PDE4BKDM4EALDH1A1 | |
| SCHEMBL3217076 | 0.80 | PDE4B (0.65) | PDE4BKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3223459 | 0.80 | PDE4B (0.70) | PDE4B | |
| SCHEMBL13425139 | 0.79 | PDE4B (1.00) | PDE4B | |
| SCHEMBL3216854 | 0.78 | PDE4B (0.63) | PDE4BKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3203511 | 0.78 | PDE4B (0.44) | PDE4BKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4115895 | 0.77 | PDE4B (0.73) | PDE4B | |
| SCHEMBL2170575 | 0.77 | PDE4B (0.53) | PDE4B | |
| SCHEMBL12334435 | 0.77 | PDE4B (0.50) | PDE4BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | PDE5A, PDE3A, PDE2A | PDE4B 9/4885KDM4E 749/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.